Professional and Student Affairs, Presbyterian CollegeSchool of Pharmacy, Clinton, SC, USA.
Am J Health Syst Pharm. 2011 Jun 1;68(11):1032-5. doi: 10.2146/ajhp100335.
The visual compatibility of hypertonic saline solution with various other drugs used for nebulizer therapy in cystic fibrosis (CF) was assessed.
Nebulized hypertonic saline solution has proved to be an effective adjunctive therapy for management of CF-related respiratory symptoms. Admixing of hypertonic saline solution and standard medications for nebulizer delivery has been suggested as a way to reduce the time-treatment burden on patients with CF, but that practice has been discouraged due to concerns about potential incompatibilities that could lead to precipitate formation (in the nebulizer or airway) and impeded drug delivery. For the study described here, visual and turbidimetric testing was conducted to assess the compatibility of admixtures of hypertonic saline solution and 11 medications widely used in CF (acetylcysteine, albuterol, atropine, cromolyn sodium, dexamethasone, glycopyrrolate, ipratropium, metaproterenol, sodium bicarbonate, terbutaline, and tobramycin). Three samples each of admixtures of the 11 drugs and 7% sodium chloride (experimental samples) or sterile water for injection (control samples) were prepared. The testing procedure entailed four turbidimetry measurements obtained at 15-minute intervals, as well as visual checks for signs of incompatibility (e.g., haze, particle or gas formation, alteration of color); analysis of variance was used to evaluate differences in test results between the experimental and control samples.
Ten of the 11 medications assessed were visually compatible with 7% sodium chloride solution, as determined by serial turbidimetric testing and visual inspection; only cromolyn sodium was found to be visually incompatible with hypertonic saline.
Eleven medications used in nebulizers for the treatment of CF were visually compatible with 7% sodium chloride solution.
评估高渗盐水溶液与用于囊性纤维化（CF）雾化治疗的各种其他药物的视觉相容性。
雾化高渗盐水溶液已被证明是治疗 CF 相关呼吸道症状的有效辅助治疗方法。建议将高渗盐水溶液与用于雾化输送的标准药物混合，以减少 CF 患者的治疗负担，但由于担心可能导致沉淀形成（在雾化器或气道中）和药物输送受阻的潜在不相容性，该做法已被劝阻。在本文描述的研究中，进行了目视和浊度测试，以评估高渗盐水溶液与 CF 中广泛使用的 11 种药物（乙酰半胱氨酸、沙丁胺醇、阿托品、色甘酸钠、地塞米松、格隆溴铵、异丙托溴铵、特布他林、碳酸氢钠、叔丁喘宁和妥布霉素）的混合物的相容性。每种药物各制备了 3 个混合物和 7%氯化钠（实验样品）或无菌注射用水（对照样品）的混合物样本。测试程序包括在 15 分钟间隔内进行四次浊度测量，以及目视检查不相容性的迹象（例如，浑浊、颗粒或气体形成、颜色变化）；方差分析用于评估实验样品和对照样品之间测试结果的差异。
在所评估的 11 种药物中，有 10 种药物通过连续浊度测试和目视检查被确定与 7%氯化钠溶液在视觉上相容；只有色甘酸钠被发现与高渗盐水在视觉上不相容。
用于治疗 CF 的 11 种雾化器药物与 7%氯化钠溶液在视觉上相容。
